USTR has initiated a Section 301 investigation into Germany’s persistent underpayment for innovative pharmaceutical products, with a comment docket opened June 25, 2026 and a deadline of August 10, 2026. The notice of initiation was published June 18, 2026. This investigation could lead to tariffs or other trade measures against Germany.
Official NewsUstrUnited States
USTR Initiates Section 301 Investigation into Germany’s Pharmaceutical Pricing Practices
Original: Section 301 – Germany’s Persistent Underpayment for Innovative Pharmaceutical Products